Megan A Waldrop

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2213444/publications.pdf

Version: 2024-02-01

28	650	567281 15	610901 24
papers	citations	h-index	g-index

32	32	32	936
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy. Human Mutation, 2022, 43, 511-528.	2.5	16
2	Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology, 2022, 98, .	1.1	6
3	Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatric Pulmonology, 2021, 56, 710-720.	2.0	31
4	Spinal Muscular Atrophy. Seminars in Pediatric Neurology, 2021, 37, 100878.	2.0	35
5	Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle and Nerve, 2021, 64, 153-155.	2.2	11
6	Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Human Gene Therapy, 2021, 32, 1346-1359.	2.7	8
7	Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatric Neurology, 2021, 122, 21-26.	2.1	5
8	Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Human Gene Therapy, 2021, 32, 882-894.	2.7	29
9	Truncating variants in UBAP1 associated with childhoodâ€onset nonsyndromic hereditary spastic paraplegia. Human Mutation, 2020, 41, 632-640.	2.5	15
10	Homozygous variants in AMPD2 and COL11A1 lead to a complex phenotype of pontocerebellar hypoplasia type 9 and Stickler syndrome type 2. American Journal of Medical Genetics, Part A, 2020, 182, 557-560.	1.2	5
11	Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Pediatric Neurology, 2020, 113, 15-20.	2.1	14
12	Spinal Muscular Atrophy in the Treatment Era. Neurologic Clinics, 2020, 38, 505-518.	1.8	19
13	Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. Pediatrics, 2020, 146, .	2.1	82
14	Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review. Journal of Neuromuscular Diseases, 2020, 7, 217-229.	2.6	18
15	The Genotypic and Phenotypic Spectrum of BICD2 Variants in Spinal Muscular Atrophy. Annals of Neurology, 2020, 87, 487-496.	5.3	18
16	A Novel De Novo Heterozygous SCN4a Mutation Causing Congenital Myopathy, Myotonia and Multiple Congenital Anomalies. Journal of Neuromuscular Diseases, 2019, 6, 467-473.	2.6	9
17	Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics, 2019, 50, 096-102.	0.6	28
18	Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genetics in Medicine, 2019, 21, 2713-2722.	2.4	28

#	Article	IF	Citations
19	Current Treatment Options in Neurologyâ€"SMA Therapeutics. Current Treatment Options in Neurology, 2019, 21, 25.	1.8	47
20	Update in Duchenne and Becker muscular dystrophy. Current Opinion in Neurology, 2019, 32, 722-727.	3.6	71
21	Low-level dystrophin expression attenuating the dystrophinopathy phenotype. Neuromuscular Disorders, 2018, 28, 116-121.	0.6	27
22	Lowâ€level expression of EPG5 leads to an attenuated Vici syndrome phenotype. American Journal of Medical Genetics, Part A, 2018, 176, 1207-1211.	1.2	9
23	In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis. Journal of Physical Education and Sports Management, 2018, 4, a003160.	1.2	14
24	ClinicopathologicÂConference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet. Pediatric Neurology, 2017, 74, 11-14.	2.1	6
25	Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic Î²-Cells and the Involvement of Neuroligin in Insulin Secretion. Endocrinology, 2008, 149, 6006-6017.	2.8	64
26	Release of Glutamate Decarboxylase-65 into the Circulation by Injured Pancreatic Islet Î²-Cells. Endocrinology, 2007, 148, 4572-4578.	2.8	19
27	A Highly Sensitive Immunoassay Resistant to Autoantibody Interference for Detection of the Diabetes-Associated Autoantigen Glutamic Acid Decarboxylase 65 in Blood and Other Biological Samples. Diabetes Technology and Therapeutics, 2006, 8, 207-218.	4.4	15
28	An evaluation of onasemnogene abeparvovec for Spinal Muscular Atrophy (SMN1). Expert Opinion on Orphan Drugs, 0, , .	0.8	0